PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
about
Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomyCoadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic EffectsModulation of Autophagy by Sorafenib: Effects on Treatment ResponseNovel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of CardiologyPhosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and CognitionEpigenetic modulation as a therapeutic approach for pulmonary arterial hypertensionThe CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the HeartRecent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsInhibition of Phosphodiesterase 5 and Increasing the Level of Cyclic Guanosine 3',5' Monophosphate by Hydroalcoholic Achillea wilhelmsii C. Koch Extract in Human Breast Cancer Cell Lines MCF-7 and MDA-Mb-468.From rapalogs to anti-aging formula.Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease.Chronic Inhibition of PDE5 Limits Pro-Inflammatory Monocyte-Macrophage Polarization in Streptozotocin-Induced Diabetic MiceImpact of Mitochondrial Ca2+-Sensitive Potassium (mBKCa) Channels in Sildenafil-Induced Cardioprotection in Rats.Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95Doxorubicin induced heart failure: Phenotype and molecular mechanisms.Downregulation of GSTK1 Is a Common Mechanism Underlying Hypertrophic Cardiomyopathy.VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection.Icariside II Effectively Reduces Spatial Learning and Memory Impairments in Alzheimer's Disease Model Mice Targeting Beta-Amyloid Production.Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?Erectile dysfunction and its management in patients with diabetes mellitus.PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.Hydrogen sulfide, an enhancer of vascular nitric oxide signaling: mechanisms and implications.A Combination of Leucine, Metformin, and Sildenafil Treats Nonalcoholic Fatty Liver Disease and Steatohepatitis in Mice.Effects of cyclic nucleotide phosphodiesterases (PDEs) on mitochondrial skeletal muscle functions.Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.Protective approaches against myocardial ischemia reperfusion injuryPDE5 Inhibitors-Loaded Nanovesicles: Physico-Chemical Properties and In Vitro Antiproliferative Activity.PDE5 Inhibitor Tadalafil and Hydroxychloroquine Cotreatment Provides Synergistic Protection against Type 2 Diabetes and Myocardial Infarction in Mice.Inhibition of PDE5A1 guanosine cyclic monophosphate (cGMP) hydrolysing activity by sildenafil analogues that inhibit cellular cGMP effluxPDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxidePDE5 Overexpression in Well-Differentiated Thyroid Carcinomas Is Associated with Lymph Node Metastasis.Chronic treatment with novel nanoformulated micelles of rapamycin, Rapatar, protects diabetic heart against ischaemia/reperfusion injury.Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species.Phosphodiesterase type 5 and cancers: progress and challenges.Phosphodiesterase-5 inhibition preserves exercise-onset vasodilator kinetics when NOS activity is reduced.Effects of chronic administration of the phosphodiesterase inhibitor vardenafil on serum levels of adrenal and testicular steroids in men with type 2 diabetes mellitus.PDE5 inhibition eliminates cancer stem cells via induction of PKA signaling.
P2860
Q26740135-86B778F9-8C9E-4DC8-BDA2-9DA6635526E8Q26741423-D35EE4A0-D721-48C0-9D24-B850643D6C73Q26745320-2FD7C3AB-B03E-4BAD-BB47-ABAFCFDFE498Q26746978-91692856-AAA3-4167-A30C-1471CEBE2E38Q26765793-5724E8B5-83CA-4EBF-85B3-245F397B489BQ26771954-A7FC5A1C-907B-4EE4-B474-945A88B596E3Q26801345-D9D62AFD-742B-4FE3-9F7C-8AAFD649B0DCQ28079006-048E2693-487E-4B8F-AE1A-718CBC9FB060Q28087776-A53C508C-A7BA-43EF-AAA6-7B9552494BD8Q33562863-FDB0E527-9BA4-4D68-9644-CF3DE126ADA9Q33829205-CA699EA5-680A-44EA-AE10-66844FC794ECQ34531894-A2915777-5EC5-4C23-81DA-AF0F2C84C611Q35593122-B3F1C7BB-133E-4A7C-81D7-DFD026C1BB46Q35869812-1294818B-BEAF-458D-A988-23FC18F56512Q36782452-AEF47721-0026-4D4F-A64B-76473B730ADAQ36912561-38F9C621-A0EE-4D21-8856-78DCCA8CDC3CQ36999686-F1AB923A-C19E-464B-80D2-287636D61AB3Q37469455-EEFF909C-3D5A-42A6-B9D9-2558B931F3D0Q37685356-AC03CB14-5A52-485C-B433-AD0CFE994C01Q37696624-71DE95CF-7214-445D-9298-84023F2D5ECAQ38542767-3B580E97-C6D0-4B72-9F27-792243B1A4EBQ38615555-3627A5E2-A2EE-44CD-9ADE-9129CA985319Q38721255-BA868B84-C468-489A-86DA-EB69BC98F07EQ38815890-57248E1F-840A-47F3-AB32-B80831E9F852Q38991916-2B2495C3-4E0A-4199-A03F-6A6940553F0CQ39044686-CB16B9AD-CDD5-4EC0-BFAB-355A79492504Q39048399-C27F8F7B-F0E3-426A-A881-3F3B1FDB707DQ39141728-0CE9E2E3-2AE1-4CA6-A775-7CB70EC47631Q41381059-A8EA0EB1-8E64-47CF-B5FB-E9AEDAB03C82Q41814211-AA3B66D3-0AC4-4CB7-A880-F6A853E894A9Q41913523-F65D9B30-A22F-4FA8-9A0A-44729D4E5401Q42260951-907FD3DB-78E7-4696-8B78-E6EFB0B44499Q42316209-E2FCF50F-A5E6-47A9-BF80-6E6AD5D33AD3Q43268349-282524E0-1730-4CD1-AFFD-0AAE5BA95765Q45068944-E971A8E2-06B5-427A-A20D-1326723B4B44Q46238888-95E90847-B590-4F4B-BD76-EFFEAD811B1FQ47171803-2C96E9F0-93AD-423A-9F42-2DFACCDD4D0CQ47855023-F3CBE26B-AE9D-4F77-8447-FAA8DE141469Q48115926-963F446C-0834-44AA-91E3-E29D3B25F070Q48507592-D23FC071-4AD3-45F3-922E-E2BC7AB5178F
P2860
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
@ast
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
@en
type
label
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
@ast
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
@en
prefLabel
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
@ast
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
@en
P2093
P2860
P1476
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
@en
P2093
David Durrant
Fadi N Salloum
Rakesh C Kukreja
P2860
P356
10.1016/J.PHARMTHERA.2014.10.003
P577
2014-10-31T00:00:00Z